Washington.— The Modern pharmaceutical company It has announced that it is developing against the vaccine. coronavirus A 94.5% efficiency According to a report, it meets the performance criteria required for marketing.
In the note, the company affirms that this is a “better day” in the fight against the corona virus, which it claims to have met the criteria established in the protocol. Read its effectiveness He will present the relevant documents in the coming days. Final approval.
The study, known as the Cove study, recruited more than 30,000 participants. United States The report says that it has been carried out National Institute of Allergy and Infectious Diseases (NIAID) and US Institute of Health, part of it National Institutes of Health (NIH) y Biomedical Company.
The results will come immediately Similar results from Pfizer And build confidence that vaccines will help kill infection. Both companies have used a new approach to design their vaccines.
Moderna has created one “RNA vaccine”That is, a part of the genetic code of the coronavirus is injected into the body, which allows the immune system to produce enough proteins to train.
As the Modern Report explains, the main focal point of the study is based on the analysis Patients with Covit-19 The second dose of the vaccine was confirmed and judged two weeks later.
“This first interim analysis was based on 95 cases, of which 90 cases were found in the group of people who received the Govit-19 placebo, compared to the five cases found in the vaccinated group,” it says in the ad.
As a second endpoint, the eleven severe cases developed in the placebo group, not the vaccine.
In 95 Covid-19 cases, 15 adults (over 65) and 20 participants were identified as belonging to different communities (including 12 Hispanics or Latinos, 4 Blacks or African Americans, 3 Asian Americans, and 1 multi-ethnic group).
When reviewing the contraindications, Modernna says, it was concluded that “in general, the vaccine was well tolerated” and that “most of the adverse events were of mild or moderate severity” and of short duration.
“Severe cases with a frequency of more than 2% or equivalent after the first dose include pain at the injection site (2.7%), followed by fatigue (9.7%), myalgia (8.9% ), headache at the injection site and redness after the second dose.
The company said in a statement: “This is a crucial moment in the development of our Govt-19 vaccine candidate. We have been chasing this virus since the beginning of January, with the goal of protecting as many people as possible. People all over the world ”.
“This positive interim analysis from our phase 3 study has provided us with the first clinical validation that our vaccine can prevent COVID-19 disease, including acute illness,” Stephen Bonsell said in a statement.